Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant- eligible patients with non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 17, Issue 12, 1999, Pages 3776-3785

  Moskowitz, Craig H ^a   Bertino, Joseph R ^a   Glassman, Jill R ^a   Hedrick, Eric E ^a   Hunte, Sonia ^a   Coady Lyons, Nancy ^a   Agus, David B ^a   Goy, Andre ^a   Jurcic, Joseph ^a   Noy, Ariela ^a   O'Brien, James ^a   Portlock, Carol S ^a   Straus, David S ^a   Childs, Barrett ^a   Frank, Richard ^a   Yahalom, Joachim ^a   Filippa, Daniel ^a   Louie, Diane ^a   Nimer, Stephen D ^a   Zelenetz, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMATOPOIETIC STEM CELL; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032761285     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.12.3776     Document Type: Article

References (38)

1. Landis SH, Murray T, Bolden S, et al: Cancer Statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Philip T, Guglielmi C, Hagenbeek A, et al: ABMT as compared with salvage chemotherapy in relapses of chemotherapy sensitive NHL. N Engl J Med 333:1540-1545, 1995
3. Philip T, Armitage JO, Spitzer G, et al: High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate or high grade NHL. N Engl J Med 316:1493-1498, 1987
4. Gulati S, Yahalom J, Acaba L, et al: Treatment of patients with relapsed and resistant NHL using total body irradiation, etoposide, and cyclophosphamide and ABMT. J Clin Oncol 10:936-943, 1992
5. Vose JM, Anderson JR, Kessinger A, et al: High dose chemotherapy and ASCT for aggressive NHL. J Clin Oncol 11:1846-1853, 1993
6. Gianni AM, Siena S, Bregni M, et al: GM-CSF to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 334:580-584, 1989
7. Velasquez WS, Cabanillas F, Salavador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988
8. Velasquez WS, McLaughlin P, Tucker W, et al: ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma. J Clin Oncol 12:1169-1176, 1994
9. Oliveri A, Offidani M, Ciniero L, et al: DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 16:85-93, 1995
10. Press OW, Livingston R, Mortimer J, et al: Treatment of relapsed NHL with dexamethasone, high dose cytarabine and cisplatin before BMT. J Clin Oncol 9:423-431, 1991
11. Girouard C, Dufresne J, Imrie K, et al: Salvage chemotherapy with mini-BEAM for relapsed or refractory NHL prior to ABMT. Ann Oncol 8:675-681, 1997
12. Reiser M, Josting A, Dias P, et al: Dexa-BEAM is not effective in patients with relapsed or resistant aggressive NHL. Leukemia Lymphoma 33:305-312, 1999
13. Kroger N, Zeller W, Fehse N, et al: Mobilizing peripheral blood stem cells with high dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Hematol 102:1101-1106, 1998
14. Dreger P, Kloss M, Peterson B, et al: Autologous progenitor cell transplantation: Prior exposure to stem cell toxic drugs determines yield and engraftment of PBPCs but not of bone marrow grafts. Blood 86:3970-3978, 1995
15. Dreger P, Marquardt P, Haferlach T, et al: Effective mobilization of PBPCs with Dexa-BEAM and G-CSF: Timing of harvesting and composition of the leukapheresis product. Br J Cancer 68:950-957, 1993
16. Moskowitz CH, Nimer SD, Glassman JR, et al: The International Prognostic Index predicts for outcome following ASCT in relapsed and primary refractory NHL. Bone Marrow Transplant 23:561-567, 1999
17. The National Cancer Institute sponsored study of classification of NHL: Summary and description of a working formulation for clinical usage-The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2122, 1982
18. Harris NL, Jaffee ES, Stein H, et al: A revised European-American classification for lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
19. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1754, 1989
20. Moskowitz CH, Stiff PS, Gordon MS, et al: Recombinant methionyl stem cell factor and filgrastim for PBPC mobilization and transplantation in non-Hodgkin's lymphoma patients: Results of a phase I/II trial. Blood 89:3136-3147, 1997
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assos 53:457-481, 1958
22. SAS Institute Inc: SAS/STAT User's Guide, Version 6, Volume 2. Cary, NC, SAS Institute, 1989, chapter 26
23. Hosmer DW Jr, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989, pp 38-81
24. O'Brien JP, O'Keefe P, Alvarez A, et al: The NHL-15 protocol for diffuse aggressive lymphomas: Two year median follow-up on the first 100 patients. Proc Am Soc Clin Oncol 14:1230, 1995 (abstr)
25. Collett D: Modelling Survival Data in Medical Research. London, United Kingdom, Chapman and Hall, 1994, chapter 3, pp 53-106
26. Prince HM, Imrie K, Crump M, et al: The role of intensive therapy and ASCT for chemotherapy sensitive relapsed and primary refractory NHL: Identification of major prognostic groups. Br J Hematol 92:880-889, 1996
27. Kreuk AM, Ossenkoppele GJ, Meijer CJLM, et al: Prognostic factors for survival of NHL patients treated with high dose therapy and ABMT. Bone Marrow Transplant 17:963-970, 1996
28. Moskowitz CH, Glassman JR, Wuest D, et al: Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 4:311-316, 1998
29. Wilson WH, Jain V, Bryant G, et al: Phase I and phase II study of high-dose ifosfamide, carboplatin and etoposide with autologous bone marrow rescue in patients with lymphomas and solid tumors. J Clin Oncol 10:1712-1722, 1992
30. Wheeler C, Shulman LN, Elias A, et al: Sequential ifosfamide, carboplatin and etoposide with steroids and cyclophosphamide/G-CSF mobilized PBPC support (SPICE) in relapsed lymphoma. Proc Am Soc Clin Oncol 14:913, 1995 (abstr)
31. Vose JM: Dose-intensive ifosfamide for treatment of NHL. Semin Oncol 23:33-37, 1996 (suppl 6)
32. Haim N, Ben Shahar M, Faraggi N, et al: DICE as second line therapy in patients with NHL. Cancer 80:1989-1996, 1997
33. Meanwell CA, Blake AE, Blackledge G, et al: Encephalopathy associated with ifosfamide/mesna therapy. Lancet 1:406-407, 1985
34. Antman KH, Elias A, Ryan L: Ifosfamide and mesna: Response and toxicity at standard and high dose schedules. Semin Oncol 17:68-73, 1990 (suppl 4)
35. Cerny T, Castiglione M, Brunner K, et al: Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 335:175, 1989 (letter)
36. Schmitz N, Linch DC, Dreger P, et al: Randomized trial of filgrastim-mobilized PBPCT vs ABMT in lymphoma patients. Lancet 347:353-357, 1996
37. Vescio R, Schiller G, Stewart AK, et al: Multicenter phase III trial to evaluate CD34+ selected vs. unselected PBPCT in multiple myeloma. Blood 93:1858-1868, 1999
38. Moskowitz CH, Nimer SD, Gabrilove J, et al: A randomized, double blind placebo controlled trial of PEG-MGDF in NHL patients receiving ICE. Proc Am Soc Clin Oncol 17:295, 1998 (abstr)